Oncogenic PI3K and its role in cancer

@article{Samuels2006OncogenicPA,
  title={Oncogenic PI3K and its role in cancer},
  author={Yardena Samuels and Kajsa Ericson},
  journal={Current Opinion in Oncology},
  year={2006},
  volume={18},
  pages={77–82}
}
Purpose of review The purpose of this review is to examine the contribution of the PI3K signaling pathway to the development of human tumors and to propose further studies to elucidate how to develop therapeutics for patients with mutations in this pathway. Recent findings More than 30% of various solid tumor types were recently found to contain mutations in PIK3CA, the catalytic subunit of PI3K. Further analysis of key genes in this pathway identified an additional eight genes altered in… 
View on Wolters Kluwer
weizmann.ac.il
483 Citations
Highly Influential Citations
14
Background Citations
207
Methods Citations
1
Results Citations
2

483 Citations

Citation Type

Citation Type

The favorable impact of PIK3CA mutations on survival: an analysis of 2587 patients with breast cancer
TLDR
It is shown that patients with tumors harboring a PIK3CA mutation have a better clinical outcome than those with a wild-type Pik3CA gene, and this improved prognosis may pertain only to patients with mutations in the kinase domain of p110α and to postmenopausal women with estrogen receptor-positive breast cancer.
Spectrum of Phosphatidylinositol 3-Kinase Pathway Gene Alterations in Bladder Cancer
TLDR
The lack of redundancy of alterations suggests that single-agent PI3K-targeted therapy may not be successful in these cancers, and a well-characterized series of cell lines are provided for use in preclinical studies of targeted agents.
The PI3K/Akt/mTOR signaling pathway in gastric cancer; from oncogenic variations to the possibilities for pharmacologic interventions.
The impact of heterogeneity in phosphoinositide 3-kinase pathway in human cancer and possible therapeutic treatments.
The PKB/AKT pathway in cancer.
  • A. Carnero
  • Biology
    Current pharmaceutical design
  • 2010
TLDR
Evidence indicates that the AKT pathway is a promising potential target for cancer chemotherapy by indicating that PI3Ks, PDK1, AKT and mTOR are heavily targeted for therapy in different ways.
Comparing the roles of the p110α and p110β isoforms of PI3K in signaling and cancer.
TLDR
The current understanding of the upstream receptor regulation of the two PI3K isoforms and their roles in cancer as well as their functional requirements in downstream signaling cascades are summarized.
Phosphatidylinositol-3-OH Kinase or RAS Pathway Mutations in Human Breast Cancer Cell Lines
TLDR
There is a fine distinction between the signaling activators and downstream effectors of the oncogenic PI3K and RAS pathways in breast epithelium and those in other tissues.
Targeting the PI3K/Akt signaling pathway in gastric carcinoma: A reality for personalized medicine?
TLDR
The common dysregulation of PI3K/Akt/mTOR pathway in GC and the various types of single or dual pathway inhibitors under development that might have a superior role in GC treatment are reviewed and the recent developments in identification of predictive biomarkers are summarized.
The Pathogenic Role of PI3K/AKT Pathway in Cancer Onset and Drug Resistance: An Updated Review
TLDR
The emerging role of the PI3K/Akt pathway is highlighted by underline the involvement of this pathway in patho-physiological cell survival mechanisms, emphasizing its key role in the development of drug resistance.
The pan-cancer analysis of gain-of-functional mutations to identify the common oncogenic signatures in multiple cancers.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 73 REFERENCES
Functional analysis of PIK3CA gene mutations in human colorectal cancer.
TLDR
Results show that almost all the colon cancer-associated PIK3CA mutations are functionally active so that they are likely to be involved in carcinogenesis.
Mutations of PIK3CA in gastric adenocarcinoma
TLDR
The data suggested that activation of the PI3K signalling pathway in gastric cancer may be achieved through up-regulation or mutation of PIK3CA, in which the latter may be a consequence of mismatch repair deficiency.
The biology and clinical relevance of the PTEN tumor suppressor pathway.
  • I. Sansal, W. Sellers
  • Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2004
TLDR
It is raised the possibility that drugs targeting these kinases, or PI3K itself, might have significant therapeutic activity in PTEN-null cancers and phase I and phase II trials of inhibitors of mTOR are underway.
Functional Analysis of PIK 3 CA Gene Mutations in Human Colorectal Cancer
TLDR
Results show that almost all the colon cancer–associated PIK3CA mutations are functionally active so that they are likely to be involved in carcinogenesis.
Title Mutations of PIK 3 CA in gastric adenocarcinoma
TLDR
The data suggested that activation of the PI3K signalling pathway in gastric cancer may be achieved through up-regulation or mutation of PIK3CA, in which the latter may be a consequence of mismatch repair deficiency.
Frequent Mutation of the PIK3CA Gene in Ovarian and Breast Cancers
TLDR
These data indicate that mutations of PIK3CA play an oncogenic role in substantial fractions of ovarian and breast carcinomas, and in consideration of mutation of other components of the PI3K-AKT pathway in both tumor types, confirm the major oncogens role of this pathway in ovarian and Breast carcinomas.
Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic.
  • Sohye Kang, A. Bader, P. Vogt
  • Biology, Chemistry
    Proceedings of the National Academy of Sciences of the United States of America
  • 2005
TLDR
The inhibitor of TOR, rapamycin, strongly interferes with cellular transformation induced by the PI3-kinase mutants, suggesting that the TOR and its downstream targets are essential components of the transformation process.
PIK3CA is implicated as an oncogene in ovarian cancer
TLDR
It is shown that PIK3CA is frequently increased in copy number in ovarian cancers, that the increased copy number is associated with increased Pik3CA transcription, p110α protein expression and PI3-kinase activity and that treatment with the PI3 -kinase inhibitor LY294002 decreases proliferation and increases apoptosis.
Somatic mutation and gain of copy number of PIK3CA in human breast cancer
TLDR
The frequent and clustered mutations within PIK3CA make it an attractive molecular marker for early detection and a promising therapeutic target in breast cancer.
Essential Role of AKT-1/Protein Kinase Bα in PTEN-Controlled Tumorigenesis
TLDR
It is shown that AKT-1 is one of the major downstream effectors of PTEN in ES cells and that activation of AKT -1 is required for both the cell survival and cell proliferation phenotypes observed in Pten −/− ES cells.
...
1
2
3
4
5
...